Clinical trial registry record

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 18, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03525600
Last registry update
June 18, 2023
Status
Completed
Phase
Phase 3
Sponsor
Apellis Pharmaceuticals, Inc.
Enrollment
621
Countries
United States, Argentina, Australia, Brazil, Canada, Czechia, France, Germany, Israel, Italy, New Zealand, Poland, Puerto Rico, Spain, United Kingdom
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
621
Population
ALL · 60 Years
Duration
2018-08-31 to 2022-06-20
Intervention
APL-2; Sham Procedure
Comparator
Not reported
Outcomes measured
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — Baseline (scree…; LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24 — Baseline (screening) and Mo…; Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24 — From Baseline (screening) through Month 24; LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24 — Baseline (screening) and…; LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24 — Baseline (screenin…; LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON